Drugs / XMT-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00455052 | Mar → Dec 2011 | non-small cell lung carcinoma, small cell lung carcinoma | Mersana Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XMT-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00455052 ↗ |
| Route | Intravenous | “XMT-1001 is administered as an IV infusion once every 21 days.” NCT00455052 ↗ |